All In Biotech

Drug Trial Radar · NCT05744687

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Randomized, Double-blind, Placebo-controlled, Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 374 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

374

Planned (sponsor's estimate)

Start

Apr 24, 2023

Primary completion

May 31, 2026

Study completion May 31, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer

Conditions

  • Locally Advanced or Metastatic Breast Cancer

Interventions

  • SPH4336 Tablets 400mgDrug

    SPH4336 Tablets :Orally, 400mg once a day; 28 days/cycle Letrozole tablets :Orally, 2.5mg once a day; 28 days/cycle

  • SPH4336 Tablets PlaceboDrug

    SPH4336 Tablets Placebo:Orally,28 days/cycle Letrozole tablets :Orally, 2.5mg once a day; 28 days/cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. response rate (ORR)Time frame: Approximately 3years
  2. Progression-free survival (PFS)Time frame: Approximately 3years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Affiliated Cancer Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • The Affiliated Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • AnYang Tumor Hospital

    Anyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China · Recruiting

  • The Second Norman Bethune Hospital of Jilin Univer

    Changchun, Jilin, China · Recruiting

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.